212 related articles for article (PubMed ID: 22028796)
1. Active and passive immunization with rHyr1p-N protects mice against hematogenously disseminated candidiasis.
Luo G; Ibrahim AS; French SW; Edwards JE; Fu Y
PLoS One; 2011; 6(10):e25909. PubMed ID: 22028796
[TBL] [Abstract][Full Text] [Related]
2. Active immunizations with peptide-DC vaccines and passive transfer with antibodies protect neutropenic mice against disseminated candidiasis.
Xin H
Vaccine; 2016 Jan; 34(2):245-251. PubMed ID: 26620842
[TBL] [Abstract][Full Text] [Related]
3. Candida albicans Hyr1p confers resistance to neutrophil killing and is a potential vaccine target.
Luo G; Ibrahim AS; Spellberg B; Nobile CJ; Mitchell AP; Fu Y
J Infect Dis; 2010 Jun; 201(11):1718-28. PubMed ID: 20415594
[TBL] [Abstract][Full Text] [Related]
4. The Hyr1 protein from the fungus Candida albicans is a cross kingdom immunotherapeutic target for Acinetobacter bacterial infection.
Uppuluri P; Lin L; Alqarihi A; Luo G; Youssef EG; Alkhazraji S; Yount NY; Ibrahim BA; Bolaris MA; Edwards JE; Swidergall M; Filler SG; Yeaman MR; Ibrahim AS
PLoS Pathog; 2018 May; 14(5):e1007056. PubMed ID: 29746596
[TBL] [Abstract][Full Text] [Related]
5. The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice.
Spellberg BJ; Ibrahim AS; Avenissian V; Filler SG; Myers CL; Fu Y; Edwards JE
Infect Immun; 2005 Sep; 73(9):6191-3. PubMed ID: 16113347
[TBL] [Abstract][Full Text] [Related]
6. Antibodies targeting
Singh S; Nabeela S; Barbarino A; Ibrahim AS; Uppuluri P
Front Immunol; 2022; 13():925821. PubMed ID: 35935947
[TBL] [Abstract][Full Text] [Related]
7. Increased resistance in BALB/c mice to reinfection with Candida albicans is due to immunoneutralization of a virulence-associated immunomodulatory protein.
Tavares D; Ferreira P; Arala-Chaves M
Microbiology (Reading); 2003 Feb; 149(Pt 2):333-339. PubMed ID: 12624195
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity.
Ibrahim AS; Spellberg BJ; Avenissian V; Fu Y; Filler SG; Edwards JE
Infect Immun; 2005 Feb; 73(2):999-1005. PubMed ID: 15664943
[TBL] [Abstract][Full Text] [Related]
9. Self-adjuvanting glycopeptide conjugate vaccine against disseminated candidiasis.
Xin H; Cartmell J; Bailey JJ; Dziadek S; Bundle DR; Cutler JE
PLoS One; 2012; 7(4):e35106. PubMed ID: 22563378
[TBL] [Abstract][Full Text] [Related]
10. Antibody response that protects against disseminated candidiasis.
Han Y; Cutler JE
Infect Immun; 1995 Jul; 63(7):2714-9. PubMed ID: 7790089
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with Secreted Aspartyl Proteinase 2 Protein from
Shukla M; Rohatgi S
Infect Immun; 2020 Sep; 88(10):. PubMed ID: 32661125
[TBL] [Abstract][Full Text] [Related]
12. Vaccine and monoclonal antibody that enhance mouse resistance to candidiasis.
Xin H; Cutler JE
Clin Vaccine Immunol; 2011 Oct; 18(10):1656-67. PubMed ID: 21832099
[TBL] [Abstract][Full Text] [Related]
13. NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.
Ibrahim AS; Luo G; Gebremariam T; Lee H; Schmidt CS; Hennessey JP; French SW; Yeaman MR; Filler SG; Edwards JE
Vaccine; 2013 Nov; 31(47):5549-56. PubMed ID: 24063977
[TBL] [Abstract][Full Text] [Related]
14. Design of a mimotope-peptide based double epitope vaccine against disseminated candidiasis.
Xin H; Glee P; Adams A; Mohiuddin F; Eberle K
Vaccine; 2019 Apr; 37(18):2430-2438. PubMed ID: 30930005
[TBL] [Abstract][Full Text] [Related]
15. Protective effect of antigen delivery using monoolein-based liposomes in experimental hematogenously disseminated candidiasis.
Carneiro C; Correia A; Lima T; Vilanova M; Pais C; Gomes AC; Real Oliveira MECD; Sampaio P
Acta Biomater; 2016 Jul; 39():133-145. PubMed ID: 27150234
[TBL] [Abstract][Full Text] [Related]
16. Comparison of two Candida mannan vaccines: the role of complement in protection against disseminated candidiasis.
Han Y; Rhew KY
Arch Pharm Res; 2012 Nov; 35(11):2021-7. PubMed ID: 23212645
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal IgM Antibodies Targeting
Youssef EG; Zhang L; Alkhazraji S; Gebremariam T; Singh S; Yount NY; Yeaman MR; Uppuluri P; Ibrahim AS
Front Immunol; 2020; 11():76. PubMed ID: 32153560
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Post-Vaccination Phagocytic Activation Using Candida albicans Killing Assays.
Li W; Hu Y
Methods Mol Biol; 2017; 1625():313-326. PubMed ID: 28584999
[TBL] [Abstract][Full Text] [Related]
19. Protection against systemic candidiasis in mice immunized with secreted aspartic proteinase 2.
Vilanova M; Teixeira L; Caramalho I; Torrado E; Marques A; Madureira P; Ribeiro A; Ferreira P; Gama M; Demengeot J
Immunology; 2004 Mar; 111(3):334-42. PubMed ID: 15009435
[TBL] [Abstract][Full Text] [Related]
20. Horizontal transmission of Candida albicans and evidence of a vaccine response in mice colonized with the fungus.
Cutler JE; Corti M; Lambert P; Ferris M; Xin H
PLoS One; 2011; 6(7):e22030. PubMed ID: 21818288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
